Rajaram Ruveena, Subramani Baskar, Abdullah Basri J J, Mahadeva Sanjiv
Division of Gastroenterology, Department of Medicine, Faculty of Medicine University of Malaya Medical Centre Kuala Lumpur Malaysia.
Nichi-Asia Life Science Sdn Bhd Petaling Jaya Malaysia.
JGH Open. 2017 Dec 7;1(4):153-155. doi: 10.1002/jgh3.12027. eCollection 2017 Dec.
Mesenchymal stem cell (MSC) transplant may offer an alternative to liver transplantation in patients with end-stage liver disease. However, its efficacy remains uncertain. MSC was performed on a 50-year-old male with decompensated (Child-Turcotte-Pugh grade C) alcoholic liver cirrhosis due to an absence of donors for adult-deceased and living-related liver transplantation. Autologous bone marrow-derived MSCs were harvested from the patient and cultured using standard protocols. The MSCs were subsequently re-administrated into the liver via hepatic intra-arterial infusion on two separate occasions. After infusion, there was an improvement in biochemical parameters (serum total bilirubin, serum albumin), and a reduction of diuretic use for ascites for up to 8 weeks. However, all biochemical and clinical parameters deteriorated on long-term follow-up without any further infusions. The patient eventually succumbed to his disease. MSC transplantation may have a clinical benefit on adult patients with end-stage liver cirrhosis, but this appears to be transitory.
间充质干细胞（MSC）移植可能为终末期肝病患者提供肝移植的替代方案。然而，其疗效仍不确定。一名50岁男性因缺乏成人已故供体和活体亲属肝移植供体，患有失代偿性（Child-Turcotte-Pugh C级）酒精性肝硬化，接受了MSC治疗。从患者身上采集自体骨髓来源的间充质干细胞，并使用标准方案进行培养。随后，间充质干细胞通过肝动脉内输注分两次重新注入肝脏。输注后，生化指标（血清总胆红素、血清白蛋白）有所改善，腹水利尿剂使用量减少长达8周。然而，在长期随访且未进行任何进一步输注的情况下，所有生化和临床指标均恶化。该患者最终因病死亡。间充质干细胞移植可能对成年终末期肝硬化患者有临床益处，但这似乎是暂时的。
